eligibility_summary
Adults ≥18 with symptomatic, measurable MZL (EMZL/SMZL/NMZL, incl. disseminated) not eligible for local therapy, 1–3 prior systemic lines incl. anti‑CD20, no lenalidomide, ECOG ≤2, adequate organ function. France social security required. Exclude: transformed disease, prior mosunetuzumab/allo‑SCT, recent anticancer or IS therapy/live vaccine, CNS lymphoma, uncontrolled infection, serious viral infection/PML, active autoimmune disease, solid organ transplant, unable to receive ICT.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III R/R marginal zone lymphoma trial comparing: (A) mosunetuzumab + lenalidomide vs investigator-choice regimens: (B) rituximab + lenalidomide, (C) rituximab + bendamustine, or (D) rituximab + CHOP. Mechanisms/types: Mosunetuzumab—subcutaneous CD20×CD3 bispecific T‑cell–engaging antibody redirecting CD3+ T cells to kill CD20+ malignant B cells. Lenalidomide—oral IMiD, binds cereblon, degrades IKZF1/3, boosts T/NK activity, anti-angiogenic/antiproliferative. Rituximab—anti‑CD20 monoclonal antibody causing B‑cell depletion via ADCC, CDC, and apoptosis. Bendamustine—alkylating agent causing DNA crosslinks. CHOP: cyclophosphamide (alkylator), doxorubicin (topoisomerase II inhibitor), vincristine (microtubule inhibitor), prednisone (glucocorticoid). Targets/pathways: CD20+ B cells, CD3 T-cell activation, cereblon‑IKZF axis, Fc/complement effector pathways, DNA damage response, microtubules, topoisomerase II, glucocorticoid receptor.